Abstract: Methods for inhibiting the activity of acyl CoA-cholesterol-o-acyltransferase, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal comprise administering naringin or naringenin thereto.

Abstract: Process for preparing a lipophilic oligosaccharide antibiotic containing a nitro group using oxidizing agents and catalysts such as cobalt, manganese and copper having an oxidation state of +2 are disclosed.

Abstract: This invention provides a method for increasing the permeability of epithelial cells to a chloride ion in a subject comprising administering a permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The invention also relates to a method of treating cystic fibrosis comprising administering an epithelial cell chloride permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The benzimidazole compound having chloride channel activation activity for use in this invention includes a 2-[(pyridyl)-methylsulfinyl or -methylthio]benzimidazole derivatives and salts thereof, for instance. Specifically, these include the compounds omeprazole, lansoprazole, thimoprazole and pantoprazole.

Abstract: A method of alleviating a lower GI symptom in a human patient afflicted with a lower GI disorder and a method of treating a human patient afflicted with a lower GI disorder, including, for example, a patient afflicted with irritable bowel syndrome or a patient afflicted with functional diarrhea, are provided. Each of these methods comprises inhibiting gastric secretion by the patient, such as by administering to the patient a pharmaceutical preparation comprising an effective amount of an inhibitor of gastric secretion.

Abstract: Cosmetic/pharmaceutical/dermatological compositions suited for stimulating the immune system/defenses of a mammalian organism, via topically applying same to the skin of such organism, comprise an immune system-stimulating amount of at least one polyholoside which comprises at least one fucose structural unit, preferably a heterogeneous polyholoside, in a topically applicable, cosmetically/pharmaceutically/dermatologically acceptable vehicle, carrier or diluent therefor.

Abstract: The invention relates to new heparin derivatives from bovine or porcine heparin which have a molecular weight equal to or larger than the standard heparin, show a sulfur content which is equal to or higher than that of the starting heparin or at least 13% w/w, have an anticoagulant activity in the anti-FXa assay of less than 10% of the standard heparin it was made from , show a ratio of APTT activity over anti-FXa activity of 3-35, show a reduced prolongation of bleeding time compared to the standard heparin it was made from as measured in the rat tail after i.v. administration and show enhancement of the rate of development of coronary collaterals in dogs equal to or better than clinically used heparin. The invention also relates to processes for preparation of the new bovine and porcine heparin derivatives.

Abstract: This invention is directed to a dietary regimen and a unique combination of nutritional supplements and a method. More specifically, this invention is directed to a unique combination of nutritional supplements which provides symptomatic relief from arthritis. The unique combination of nutritional supplements of this invention is believed to function by both increasing the available (effective blood level) of anti-inflammatory agents and promotion of the healing/regenerative process in the effected joints, thus, producing unexpected and lasting symptomatic relief from the debilitating effects of both osteoarthritis and rheumatoid arthritis.

Abstract: The invention relates to carbohydrate mimetics, which inhibit the binding of selectin to carbohydrate ligands, of the formula I ##STR1## excluding the compounds sialyl-Lewis-X and -A and their derivatives which, instead of an N-acetyl group, carry the substituents N.sub.3, NH.sub.2 or OH or which, instead of fucose, carry glycerol,and pharmaceutical compositions and diagnostic agents containing these derivatives, and methods for using these pharmaceutical compositions and diagnostic agents.

Abstract: A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.

Abstract: An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is a fucose or mannose residue, have therapeutic utility via inhibition of selectins, and thus of cell adhesion.

Abstract: Heparin derivatives are disclosed that may be used to inhibit formation of metastases. One series of heparin derivatives of the invention are N-acylated with monocarboxylic acids or dicarboxylic acids and have molecular weights from about 1000 Daltons to about 30,000 Daltons. Another series of heparin derivatives of the invention have average molecular weights ranging from about 1000 to 3000 daltons, and are optionally N-acylated with residues from aliphatic monocarboxylic or dicarboxylic acids.

Abstract: The present invention provides novel methods of producing chitosan having a tap density of at least about 0.4 g/ml. In one aspect of the present invention, chitosan is selected having an average molecular mass of from about one thousand Daltons to about two million Daltons; a particle size that is smaller than 20 mesh; a viscosity of at least about 1 cps, and a percentage of deacetylation of from about 65% to about 98% A measured amount of the selected chitosan is then mixed with an amount of water that is from about two to about ten times the weight of the chitosan, and an amount of an acid that is at least about 0.1% of the weight of the chitosan. The acid is preferably an organic acid. The mixture of chitosan, water and acid is then mixed to a smooth paste, dried to a moisture content of from 0% moisture to about 20% moisture, and the particle size is preferably reduced to smaller than 20 mesh. In another aspect of the invention, chitosan is provided having a tap density of at least about 0.

Abstract: A method of treating hypovolemic shock and related shock syndromes by the administration of substantially non-anticoagulant heparinoids without the hemorrhaging problems generally associated with heparin; such syndromes include degradation of the microvascular structure, immune and gastrointestinal tract dysfunction, and multiple organ failure.

Abstract: This invention is directed to the preparation and utilization of supplemented chitin hydrogels, such as chitosan hydrogels. Further provided are biomaterials comprising same. The particular supplement delivered by the chitin hydrogel is selected as a function of its intended use. In one embodiment, this invention provides a composition of matter, comprising a chitin hydrogel or chitin-derived hydrogel, wherein the hydrogel does not inhibit full-thickness skin wound healing.

Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to 9-substituted 2-(2-n-alkoxyphenyl)purin-6-one compounds.

Abstract: Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula ##STR1## compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for their preparation.

Abstract: A process for producing polyhydroxy ethers having the formula (I) (HO).sub.(w--M) W(OV).sub.m, in which W represents an organic group and OV a structural element containing hydroxyl groups, having the formula (III) ##STR1## A multifunctional alcohol W(OH).sub.w (II) is reacted with an .alpha.,.beta.-unsaturated carbonyl compound XCH.dbd.CY--CZ.dbd.O (IV) and formaldehyde in the presence of a base. The .alpha., .beta.-unsaturated carbonyl compound (IV) and the remaining quantities of formaldehyde, multifunctional alcohol (II) and base are added continuously or periodically to an aqueous solution or suspension containing at least 10 mole % of the multifunctional alcohol (II), at least 10 to 70 mole % of the formaldehyde and at least 10 mole % of the base. Preferred multifunctional alcohols (II) are pentaerythritol, TMP and TME. Preferred carbonyl compounds (IV) are acrolein and .alpha.-alkylacrolein. New asymmetric polyhydroxy ethers are also disclosed.

Abstract: This invention describes methods for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against resistant tumor cells in mammals which comprise administering a multidrug resistant reversing agent to the mammal in connection with the administration of the cytostatic hydrophobic chemotherapeutic agent in an amount effective to increase the toxicity of the chemotherapeutic agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound. Examples of the macrocyclic lactone compounds useful in the present invention include, but are not limited to, the LL-F28249.alpha.-.lambda. series of compounds, the 23-oxo or 23-imino derivative thereof, the avermectins, the 22,23-dihydro derivatives thereof and the milbemycins. Compositions comprising the macrocyclic lactone compounds and the chemotherapeutic agents are also described herein.

Abstract: Novel Group II metal MOCVD precursor compositions are described having utility for MOCVD of the corresponding Group II metal-containing films. The complexes are Group II metal .beta.-diketonate Lewis base adducts having ligands such as: (i) amines bearing terminal NH.sub.2 groups; (ii) imine ligands formed as amine (i)/carbonyl reaction products; (iii) combination of two or more of the foregoing ligands (i)-(ii), and (iv) combination of one or more of the foregoing ligands (i)-(ii) with one or more other ligands or solvents. The source reagent complexes of barium and strontium are usefully employed in the formation of barium strontium titanate and other Group II doped thin-films on substrates for microelectronic device applications, such as intearated circuits, ferroelectric memories, switches, radiation detectors, thin-film capacitors, microelectromechanical structures (MEMS) and holoaraphic storage media.